Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 16/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL749069 | 0.82 | ALDH1A1 (0.45) | PIK3CAMTOR | |
| SCHEMBL754024 | 0.77 | NR3C2 (0.39) | PIK3CDPIK3CAMTOR | |
| SCHEMBL753108 | 0.70 | LRRK2 (0.36) | PIK3CDPIK3CAMTOR | |
| SCHEMBL24374635 | 0.69 | MTOR (0.54) | ATRATRIPPIK3CDPIK3CACHEK1 | |
| SCHEMBL11634928 | 0.69 | MTOR (0.54) | ATRATRIPPIK3CDPIK3CACHEK1 | |
| SCHEMBL27787101 | 0.68 | ATR (0.44) | ATRPDE4DATRIPPIK3CDPIK3CA | |
| SCHEMBL24374692 | 0.67 | BTK (0.48) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL30629341 | 0.65 | PIK3CD (0.58) | ATRATRIPPIK3CDPIK3CACHEK1 | |
| SCHEMBL28902833 | 0.65 | ATR (0.65) | ATRATRIPPIK3CDPIK3CACHEK1 | |
| SCHEMBL11632971 | 0.64 | MTOR (0.48) | ATRATRIPPIK3CDPIK3CACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | ATR 315/4885PDE4D 2834/4885ATRIP 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.